

ProteoTech's CEO, Steve Runnels, Featured in Recent Xconomy/Seattle December 20, 2010 Article

ProteoTech's CEO, Steve Runnels, was recently featured in a December 20, 2010 Xconomy article that can be found at <http://www.xconomy.com/seattle/2010/12/20/fighting-alzheimers-new-hope-in-a-new-year-through-innovation/>. In the article, Mr. Runnels discussed the ongoing and significant need to identify effective diagnosis and treatments for Alzheimer's disease. Mr. Runnels provides a current review and important recent developments of Alzheimer's disease in five areas:

1. Greater understanding of the disease through improved knowledge of protein interactions associated with Alzheimer's disease.
2. Improved diagnoses of Alzheimer's disease through technological developments.
3. Development of better biomarkers in order to refine diagnosis and potential treatment of Alzheimer's disease.
4. Enhanced knowledge provided to general medical practitioners to empower their patients to adopt better life style choices which may delay the onset of Alzheimer's disease.
5. A change in research and development focus from identifying compounds which treat Alzheimer's disease symptoms toward developing disease-modifying therapies which address the root cause of the disease.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. The Company is developing *Synuclein*[™] for the treatment of Parkinson's disease, EXEBRYL[®] for the treatment of Alzheimer's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called *PeptiClere*[™] for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.